Gossamer Bio Inc (NAS:GOSS)

$ 0.7298 0.0317 (4.54%) Market Cap: 165.38 Mil Enterprise Value: 34.78 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 36/100

Gossamer Bio Inc To Discuss Latest Seralutinib Open-Label Extension Data Transcript
Dec 18, 2023
Gossamer Bio Inc To Discuss Seralutinib Program Update Call Transcript
Jul 25, 2023
Gossamer Bio Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Gossamer Bio Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Gossamer Bio Inc To Discuss TORREY Topline Results Call Transcript
Dec 06, 2022
Gossamer Bio Inc at UBS Global Healthcare Conference Transcript
May 25, 2022
Gossamer Bio Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Gossamer Bio Inc To Discuss Phase 2 SHIFT-UC Topline Clinical Trial Results Call Transcript
Apr 25, 2022
Gossamer Bio Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Q4 2021 Gossamer Bio Inc Earnings Call Transcript
Mar 03, 2022

$9.04 (-2.38%)

Earnings
Q3 2021 Gossamer Bio Inc Earnings Call Transcript
Nov 08, 2021

$13.35 (+0.45%)

Earnings
Gossamer Bio Inc at Jefferies Next Generation IBD Therapeutics Summit (Virtual) Transcript
Oct 19, 2021
Gossamer Bio Inc Investor Day Transcript
Oct 11, 2021
Q2 2021 Gossamer Bio Inc Earnings Call Transcript
Aug 09, 2021

$8.36 (+1.33%)

Earnings
Gossamer Bio Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Gossamer Bio Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Q4 2020 Gossamer Bio Inc Earnings Call Transcript
Feb 25, 2021

$9.79 (-5.59%)

Earnings
Gossamer Bio, Inc. - Special Call Transcript
Feb 18, 2021
Gossamer Bio, Inc. - Special Call Transcript
Dec 15, 2020
Q3 2020 Gossamer Bio Inc Earnings Call Transcript
Nov 10, 2020

$9.26 (-0.11%)

Earnings
Gossamer Bio Inc to Discuss Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis Call Transcript
Oct 13, 2020
Gossamer Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Gossamer Bio Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 Gossamer Bio Inc Earnings Call Transcript
May 12, 2020

$15.89 (-0.59%)

Earnings
Q3 2019 Gossamer Bio Inc Earnings Call Transcript
Nov 12, 2019

$22.43 (-1.67%)

Earnings
Q2 2019 Gossamer Bio Inc Earnings Call Transcript
Aug 08, 2019

$19.51 (-1.81%)

Earnings
Gossamer Bio Inc at Bank of America Merrill Lynch Global Metals, Mining & Steel Conference Transcript
May 14, 2019
Q1 2019 Gossamer Bio Inc Earnings Call Transcript
May 14, 2019

$19.29 (-4.65%)

Earnings

Gossamer Bio Inc To Discuss TORREY Topline Results Call Transcript

Dec 06, 2022 / 01:00PM GMT

Release Date Price: $2.36 (-74.60%)

Transcript

Operator

Hello, and welcome to the Gossamer Bio TORREY Topline Results Call. (Operator Instructions) Please note, today's event is being recorded.

I'd now like to turn the conference over to your host today, Faheem Hasnain. Please go ahead.

Faheem Hasnain

Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Hello, everyone, and thank you for joining us this morning. We're here today to discuss a critical milestone in Gossamer and seralutinib history, the positive topline results of the Phase II TORREY study in patients with PAH, Pulmonary Arterial Hypertension.

Most of you have, no doubt, seen the press release we issued this morning announcing our topline results and we're looking forward to diving into the data a bit further with you on the call today.

We'll be making forward-looking statements on this call, and I encourage you to read through the details on the slide.

Now with us from the Gossamer team, we have Dr. Richard Aranda, our Chief Medical Officer; Dr. Rob Roscigno, the clinical lead of the seralutinib

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.